Identification of surface-associated antigens for tumor diagnosis and therapy
The invention relates to identifying tumor-associated genetic products and encoding nucleic acids thereof. A therapy and diagnosis of diseases in which the tumor-associated genetic products are aberrantly expressed, proteins, polypeptides and peptides which are expressed in association with tumor and the encoding nucleic acids for said proteins, polypeptides and peptides are also disclosed.
1. A method of diagnosing a cancer in a patient, which method comprises detecting and quantifying a marker in a biological sample isolated from the patient, wherein the marker is a tumor-associated antigen encoded by a nucleic acid that comprises the nucleic acid sequence of SEQ ID NO: 9, wherein the detecting comprises:
(i) contacting the biological sample with an antibody
(A) that binds specifically to the marker at an epitope in SEQ ID NO:285 or SEQ ID NO:286, or
(B) raised against a peptide consisting of SEQ ID Nos: 285 or 286; and
(ii) detecting the formation of a complex between the antibody and the marker, and comparing the amount of the marker in the biological sample to the amount of the marker in a corresponding normal tissue;
wherein the cancer is a cancer characterized by expression of the tumor-associated antigen selected from the group consisting of a gastric cancer, a breast cancer, an esophageal cancer, a pancreatic cancer, an ovary cancer, and a prostate cancer,
wherein gene expression of the tumor-associated antigen in normal somatic cells is suppressed and
wherein greater expression of the tumor-associated antigen in the biological sample as compared to corresponding normal tissue is indicative of the cancer.
2. The method of claim 1 , wherein the level of the marker in the biological sample is quantified by comparison to the level of the same marker present in a comparable normal biological sample.
3. The method of claim 1 , wherein the cancer is characterized by expression of two or more tumor-associated antigens.
4. The method of claim 1 , wherein the tumor-associated antigen is present in a complex with an MHC molecule.
5. The method of claim 4 , wherein the MHC molecule is an HLA molecule.
6. The method of claim 1 , wherein the sample comprises a body fluid, a tissue, or a combination thereof.
7. The method of claim 1 , wherein the tumor-associated antigen comprises the amino acid sequence of SEQ ID NO: 10.
8. The method of claim 1 , wherein the sample comprises a body tissue.
9. The method of claim 1 , wherein the cancer is an esophageal cancer, a pancreatic cancer, an ovary cancer, or a prostate cancer.
10. The method of claim 1 , wherein the antibody specifically binds to the marker at an epitope in SEQ ID NO:285 or SEQ ID NO:286.
11. The method of claim 1 , wherein the antibody is an antibody raised against a peptide consisting of SEQ ID NOs: 285 or 286.